Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIMPIC: Ranibizumab Re-treatment Criteria in Myopic CNV
NCT02034006Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2014
- Primary completion
- Jul 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in choroidal neovascularization (CNV), sponsored by Novartis. Started Jun 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT02034006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034006.